Evidence map›Paper›PMID 34631716›Full record

ArticleFrontiers in cell and developmental biology2021

Bone Marrow Regulatory T Cells Are a Unique Population, Supported by Niche-Specific Cytokines and Plasmacytoid Dendritic Cells, and Required for Chronic Graft-Versus-Host Disease Control.

Jemma Nicholls, Benjamin Cao, Laetitia Le Texier, Laura Yan Xiong, Christopher R Hunter, Genesis Llanes, Ethan G Aguliar, Wayne A Schroder, Simon Phipps, Jason P Lynch and 9 more

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jemma NichollsDivision of Blood and Marrow Transplant and Cellular Therapies, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States.
Benjamin CaoBiomedical Manufacturing Commonwealth Scientific and Industrial Research Organization, Melbourne, VIC, Australia.
Laetitia Le TexierImmunology Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Laura Yan XiongImmunology Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Christopher R HunterImmunology Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Genesis LlanesImmunology Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Ethan G AguliarDivision of Blood and Marrow Transplant and Cellular Therapies, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States.
Wayne A SchroderImmunology Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Simon PhippsImmunology Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Jason P LynchImmunology Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.
Huimin CaoBiomedical Manufacturing Commonwealth Scientific and Industrial Research Organization, Melbourne, VIC, Australia.
Shen Y HeazlewoodBiomedical Manufacturing Commonwealth Scientific and Industrial Research Organization, Melbourne, VIC, Australia.
Brenda WilliamsBiomedical Manufacturing Commonwealth Scientific and Industrial Research Organization, Melbourne, VIC, Australia.
Andrew D CloustonEnvoi Specialist Pathologists, Brisbane, QLD, Australia.
Christian M NefzgerAustralian Regenerative Medicine Institute, Monash University, Melbourne, VIC, Australia.
Jose M PoloAustralian Regenerative Medicine Institute, Monash University, Melbourne, VIC, Australia.
Susan K NilssonBiomedical Manufacturing Commonwealth Scientific and Industrial Research Organization, Melbourne, VIC, Australia.
Bruce R BlazarDivision of Blood and Marrow Transplant and Cellular Therapies, Department of Pediatrics, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, United States.
Kelli P A MacDonaldImmunology Department, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.

Funding

Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2M
Transgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI SHARPE, ARLENE H. · 2003 to 2023
$42.5M
Project 3: Humoral Targets and B Cell Biology in Chronic Graft-vs.-Host DiseaseP01CA142106 · NCI · DANA-FARBER CANCER INST · PI CUTLER, COREY S · 2009 to 2019
$17.5M
Enhancing Treg Therapeutic Efficacy in GVHDR01HL118979 · NHLBI · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, HIPPEN, KELI L · 2014 to 2025
$6.7M
T-CELL TARGETING FOR GVHDR01HL056067 · NHLBI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1995 to 2022
$5.4M
In Vivo Prevention of Murine GVHDR37AI034495 · NIAID · UNIVERSITY OF MINNESOTA · PI Bruce R Blazar · 2017 to 2026
$5.4M
Nongenotoxic conditioning for gene therapy and allogeneic transplantation in Fanconi anemiaR01HL147324 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Bruce R Blazar, HANS-PETER KIEM · 2020 to 2026
$4.1M
NCI NIH HHS P01 CA065493NCI NIH HHS P01 CA142106NHLBI NIH HHS R01 HL056067NHLBI NIH HHS R01 HL118979NHLBI NIH HHS R01 HL147324NIAID NIH HHS P01 AI056299NIAID NIH HHS R37 AI034495
6 · The paper itself

Abstract

Regulatory T cell (Treg) reconstitution is essential for reestablishing tolerance and maintaining homeostasis following stem-cell transplantation. We previously reported that bone marrow (BM) is highly enriched in autophagy-dependent Treg and autophagy disruption leads to a significant Treg loss, particularly BM-Treg. To correct the known Treg deficiency observed in chronic graft-versus-host disease (cGVHD) patients, low dose IL-2 infusion has been administered, substantially increasing peripheral Treg (pTreg) numbers. However, as clinical responses were only seen in ∼50% of patients, we postulated that pTreg augmentation was more robust than for BM-Treg. We show that BM-Treg and pTreg have distinct characteristics, indicated by differential transcriptome expression for chemokine receptors, transcription factors, cell cycle control of replication and genes linked to Treg function. Further, BM-Treg were more quiescent, expressed lower FoxP3, were highly enriched for co-inhibitory markers and more profoundly depleted than splenic Treg in cGVHD mice.

Indexed as

bone marrowFoxP3GVHDregulatory T cellsstem-cell transplantationTIGIT

Identifiers

PMID34631716
PMCPMC8493124

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.